Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03604198 · ClinicalTrials.gov registry record · Phase 2
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
A Phase 2 study of Cushing Syndrome, sponsored by Corcept Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
- 20
- Study locations
NCT03604198 is a Phase 2 study of Cushing Syndrome that is active but no longer recruiting, run by Corcept Therapeutics. The registered enrollment target is 125 participants, below the 166-participant average among 9 other Cushing Syndrome trials with a reported enrollment target (25% lower). The trial reports 20 study locations across 18 states.
The verdict
NCT03604198, a Phase 2 study of Cushing Syndrome, is active but no longer recruiting, sponsored by Corcept Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may benefit from continuing treatment.
Conditions Studied
Interventions
- DRUG relacorilant
Study Locations (20)
California
- Site 35 - Stanford
- Site 39 - Torrance
New York
- Site 6 - Albany
- Site 24 - New York
Arizona
- Site 49 - Phoenix
Florida
- Site 50 - Miami
Georgia
- Site 10 - Atlanta
Illinois
- Site 9 - Chicago
Indiana
- Site 1 - Indianapolis
Louisiana
- Site 5 - Metairie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2018-05-07 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03604198
The ClinicalTrials.gov registry entry for NCT03604198 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 166-participant average among 9 other Cushing Syndrome trials with a reported enrollment target (25% lower). The listed sponsor is Corcept Therapeutics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cushing Syndrome appearing as the primary indexed condition, and to 1 intervention - of which relacorilant is the first listed.
NCT03604198 reports 20 study locations spanning 18 distinct geographic areas - top geographies include California, New York, Arizona.
Frequently Asked Questions
What is clinical trial NCT03604198 about?
NCT03604198 is a clinical study titled "Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome". This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may benefit from continuing treatment.
What is the current status of trial NCT03604198?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2018-05-07. Estimated completion is 2026-12.
What conditions does trial NCT03604198 study?
This clinical trial studies the following conditions: Cushing Syndrome.
What interventions are being tested in trial NCT03604198?
The interventions under investigation include: relacorilant (DRUG).
Who is sponsoring clinical trial NCT03604198?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03604198 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cushing Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome
RECRUITING · Phase 2
-
Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome
RECRUITING · Phase 2
-
New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome
COMPLETED · Phase 2
-
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
RECRUITING · Phase 1
-
Collecting Information About Treatment Results for Patients With Cushing's Syndrome
RECRUITING
-
Recovery From Cushing Syndrome and Mild Autonomous Cortisol Secretion (MACS)
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.